Summit Therapeutics Inc. Summit Therapeutics Inc.

Summit Therapeutics Inc.

SMMT

Kedudukan dalam Saham #1707
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Harga Saham
$15.71
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$12.53B
Perubahan (1 hari)
7.35%
Perubahan (1 tahun)
-21.63%
Negara
US
Perdagangan Summit Therapeutics Inc. (SMMT)

Kategori

Healthcare
Sejarah dividen untuk Summit Therapeutics Inc. (SMMT)
Summit Therapeutics Inc. (simbol saham: SMMT) telah membuat sejumlah 0 pembayaran dividen.
Jumlah semua dividen (disesuaikan untuk pemecahan saham): 0.00
Hasil dividen (TTM): 0
Pembayaran dividen untuk Summit Therapeutics Inc. (SMMT) dari 2026 hingga 2026
Pembayaran dividen tahunan
Tahun Dividen (diselaraskan untuk pemecahan saham) Ubah
Tidak cukup data untuk tarikh yang disediakan.
Senarai semua pembayaran dividen
Tahun Dividen Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pembayaran dividen untuk syarikat serupa atau pesaing
Syarikat Jumlah pembayaran dividen Negara
0.00%
US
0.00%
US
64.00%
AU
0.00%
CH
0.00%
NL